New chemo cocktail aims to tame aggressive head and neck tumors with fewer side effects
NCT ID NCT04356170
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase II trial tested a combination of three chemotherapy drugs (cisplatin, 5-fluorouracil, and docetaxel) at adapted doses in 105 patients with locally advanced head and neck cancer that could not be surgically removed. The goal was to see if this adjusted dosing could effectively shrink tumors while reducing severe toxicity. The study measured how many patients had a successful response at 8 weeks without serious side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- chemotherapy combination (cisplatin, 5-fluorouracil, docetaxel)
- What this could lead to
- If successful, this could provide a more tolerable chemotherapy regimen for patients with inoperable head and neck cancer, potentially improving treatment response while reducing severe side effects.
- What could go wrong
- This is a phase II trial with only 105 participants and no comparison group, so results are preliminary. The chemotherapy combination still carries significant toxicity risks, and success in this early stage does not guarantee broader effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER OF HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Leon Berard
Lyon, 69008, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging technique could help doctors predict cancer treatment response
- Can less radiation be safer without sacrificing cancer control?
- New study aims to help cancer survivors manage other health problems
- Cialis and keytruda together against head and neck cancer: small trial shows promise?
- New program aims to ease the burden of head and neck cancer treatment
- Immunotherapy combo shows promise in reducing head and neck cancer recurrence